Galdmera has named new managers of its Prescription Business and Aesthetic & Corrective Business units in the United States. Chris Chapman is Galderma’s new Vice President and General Manager of Prescription Business and Alisa Lask is the new Vice President and General Manager of the Aesthetic & Corrective Business Unit.

Chris previously served as Vice President of Strategic Access for Galderma’s Prescription Business Unit. In this new role, Chris will manage Galderma's broad portfolio of prescription medications including the full line of products that treat acne, psoriasis, eczema and rosacea. He will also oversee Galderma CareConnect, a patient savings card program that offers discounts to patients on the quality dermatology prescription medications offered by Galderma.
 
Chris joined Galderma in 2015, and in his previous position as Vice President of Strategic Access was responsible for commercial payer account management and contracting, trade account management and branded consumer rebate programs.  During his tenure, Chris developed and launched the Galderma CareConnect program. The program has grown to more than 40,000 pharmacies and served more than 500,000 unique patients, and just celebrated the milestone of 1,000,000 prescriptions.
 
“Galderma has a rich portfolio of prescription products that truly change peoples’ lives,” said Chris. “I’m proud to be a part of the innovation that we deliver to both health care professionals and patients. And I look forward to leading the prescription business unit in continued advancements in skin health, especially for people suffering from skin diseases such as acne, and rosacea.”

Alisa was previously Vice President of Marketing of Aesthetic & Corrective Business. In her new role, Alisa will manage Galderma's broad portfolio of treatments -including Restylane^® Refyne, Restylane^®Defyne, Restylane^® Silk, Restylane^® Lyft with Lidocaine, Restylane^® - L and Sculptra^® Aesthetic.

"I am confident with Galderma's rich pipeline we will continue to bring solutions to the marketplace that transform category expectations, and I'm honored to lead a business unit poised to deliver a new chapter of aesthetic innovation," says Alisa in a news release.

Alisa worked at Allergan in global strategic marketing for facial aesthetics where she focused on new product planning in aesthetic innovation. Prior to that, she was Vice President of global strategic marketing at Zimmer Biomet. Additionally, Alisa spent 11 years at Eli Lilly specializing in marketing for women's health and neuroscience.

In related news, former Galderma general manager Kelly Huang, Ph.D., is now Obalon’s Chief Operating Officer. In this new role, Dr. Huang will be responsible for the key commercial functions of sales, marketing, operations, and quality assurance.